Resources from the same session
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Presenter: Myung-Ju Ahn
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
Presenter: Yi-Long Wu
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
Presenter: Makoto Nishio
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Invited Discussant LBA15 and 474O
Presenter: Sanjay Popat
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
Presenter: Byoung Chul Cho
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Presenter: Thanyanan Reungwetwattana
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast